Australia markets closed

IntegraGen SA (7N8.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.50500.0000 (0.00%)
At close: 02:54PM CEST
Full screen
Previous close0.5050
Open0.5000
Bid0.5100 x N/A
Ask0.6450 x N/A
Day's range0.5000 - 0.5100
52-week range0.4580 - 1.4100
Volume0
Avg. volume0
Market cap3.703M
Beta (5Y monthly)0.13
PE ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings date24 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    IntegraGen: Annual Results 2023 - Positive EBITDA Reflecting Tight Cost Control

    EVRY, France, April 18, 2024--Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, today announced its audited annual results for fiscal 2023, the accounts having been approved by the Board of Directors on April 5, 2024.

  • Business Wire

    IntegraGen Reports €11.8M Revenues for 2023

    ÉVRY, France, January 16, 2024--Regulatory News: IntegraGen (FR0010908723 – ALINT) (Paris:ALINT) an OncoDNA Group company specializing in the decryption of the human genome which performs interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools for oncology, today announced its non-audited revenue of €11,751k in 2023, representing a decrease of 7% compared to 2022 (excluding intra-group transactions). This decrease in revenues in 2023 is mainly due to th